The success of life sciences companies will depend on products and services not yet found in a companies offerings in the next decade. Much of those products will be brought to companies through the merger and acquisitions of small to mid-sized companies. This panel will discuss:
- When is the right time to get acquired?
- What is the survival rate of c-suite after an acquisition?
- Why is an acquisition better than a collaboration?
- What are the key issues in the due diligence process that can hurt the value of the deal?
- How does big pharma prepare for pricing negotiations and how can a smaller seller be prepared
- What types of steps can be taken to prepare a forecast that drives value negotiations
- How can this analysis be leverage in negotiating a collaborative or co-partner agreement
Panelists include: Ben Clark, Partner, Deloitte & Touche LLP; Jay Jesclard, Senior Manager, Deloitte Financial Advisory Services LLP; Linda Justice, Senior Manager, Deloitte Financial Advisory Services LLP; and Ronda Sroka, Partner, Deloitte Tax LLP.
Related Insights
05 December 2024
Consumer Class Defense Counsel
Sixth Circuit: Reliance Can Bar Class Certification Even if Not Express Element of Consumer Statutory Claim
Courts routinely refuse to certify consumer class actions under Federal Rule of Civil Procedure 23(b)(3) based on the need for an individualized showing of the reliance element of a fraud or deceptive trade practices claim.
05 December 2024
Consumer Class Defense Counsel
Office of the Comptroller of the Currency Updates “Unfair or Deceptive Acts or Practices and Unfair, Deceptive, or Abusive Acts or Practices” Booklet
Financial institutions that are regulated and supervised by the Office of the Comptroller of the Currency (OCC) should know that the OCC has recently updated its booklet on Unfair or Deceptive Acts or Practices (UDAP) and Unfair, Deceptive, or Abusive Acts or Practices.
05 December 2024
Foley Viewpoints
New Requirements for Franchise Brokers in California
On September 24, 2024, Governor Gavin Newsom signed Senate Bill 919, amending California’s Franchise Investment Law to regulate franchise brokers and franchise sales organizations.